Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Locums should stand up for their interests, say 'no' to unfair terms: PDA

The recent PDA survey showed that locum pharmacists work in a difficult environment, and most of them are dissatisfied with their jobs

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

iStock

The Pharmacists' Defence Association (PDA) has advised locum pharmacists to be vigilant about their interests and negotiate directly with their businesses, avoid working with digital platforms driven by algorithms, and be aware of regressive contract terms.

The not-for-profit organisation issued such an advisory following its survey of 1,300 UK locum pharmacists, which showed that they work in a difficult environment and that most are dissatisfied with their jobs.


Their grievances include declining rates of pay with often non-existent opportunities for negotiation, non-payment of legitimately incurred expenses, and some contractors operating unscrupulously with last-minute changes to agreed shifts and questionable contract terms.

On the other hand, with the increasing focus on 'Pharmacy First', there is an increase in their scope of work and expectations.

But past surveys have shown that competent staff are in short supply.

The PDA survey found that locum pharmacists face more barriers than their employed peers in accessing professional development and training.

Some universities bar them from taking up Independent Prescribing courses.

Many locums expressed concern that their work is not valued, though the scope of their services has increased.

The PDA observed that adverse pharmacy eco-systems have resulted in locum pharmacists accepting poor treatment in a way that many trades, such as plasterers, plumbers, and electricians, would not tolerate.

However, it observed that it doesn’t have to be like that if locum reps follow best practices.

The PDA exhorted locums to consider the collective advice from its locum representatives before entering into a contract, and think about the wider consequences of accepting terms which they truly believe are not appropriate.

Every time a locum accepts a lower rate or unfair contractual clauses, this enables unscrupulous businesses to make that the norm.

The PDA advised locums to negotiate directly with the company or the business owner.

This will help them get better rates of pay and a clearer understanding of the expectations of them in the workplace, it added.

The PDA has a dim view of platform and algorithmic working, and wants locums to avoid them.

While the contribution of a pharmacist is very different from many other “gig economy” workers, the technology and thinking behind platforms built around algorithms aim to minimise the cost to the client business while ensuring a payment is still secured for the platform owners.

The absence of the ability to negotiate a rate might be considered one of several red flags, it added.

PDA wants locums to be fully aware of the terms under which they are proposed to be engaged, and be aware of regressive contract terms.

It advised locums to decline the work if some terms appear problematic and to seek alternative work elsewhere.

While taking up a contract, Locums should take into account whether their employers are ready to pay for their travel and accommodation expenses.

If an employer does not offer reasonable travel or accommodation remuneration, or an increased rate to reflect those extra costs conferred, then deduct it from the overall payment being offered and consider again if the hourly rate is reasonable.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less